SCHEMBL5591673

SCHEMBL5591673

FC(F)(F)c1ccccc1-c1nc2[c]cccc2s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.39
KDM4E B2RXH2 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PIM1 P11309 1/20 0.36
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NOTUM Q6P988 2/20 0.35
PSMB8 P28062 1/20 0.35
TRPA1 O75762 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
TRPV1 Q8NER1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5591929 0.80 KDM4E (0.36) KDM4EALDH1A1MEN1NPC1GAA
SCHEMBL5591848 0.77 KDM4E (0.58) KDM4ENPSR1ALDH1A1MEN1NPC1
SCHEMBL5591719 0.75 TNF (0.42) KDM4ENPSR1ALDH1A1MEN1NPC1
SCHEMBL5591781 0.75 CA1 (0.33) ALDH1A1MEN1NPC1RAB9AKMT2A
SCHEMBL10422668 0.73 CASR (0.33)
SCHEMBL5540904 0.73 KDM4E (0.42) KDM4EALDH1A1HPGDMEN1NPC1
SCHEMBL3186611 0.72 MIF (0.51) HSD11B1KDM4ENPSR1PIM1ALDH1A1
SCHEMBL900779 0.72 ALDH1A1 (0.47) HSD11B1KDM4EALDH1A1HPGDMEN1
SCHEMBL5591820 0.72 ALDH1A1 (0.47) KDM4EPIM1ALDH1A1MEN1NPC1
SCHEMBL27873736 0.72 RAB9A (0.49) KDM4ENPSR1ALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007076104-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2007-07-05 WO disclosed
EP-1670794-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS Amgen Inc. (US) 2006-06-21 EP disclosed
US-20050153984-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-07-14 US disclosed
WO-2005033105-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153984-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 HSD11B1 3084/4885KDM4E 4218/4885NPSR1 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.